Trial Profile

Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Oct 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Acute myeloid leukaemia; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer
Focus Pharmacokinetics
Sponsors Bayer

Most Recent Events

03 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
03 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
30 Jan 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com